FIELD: biotechnology.
SUBSTANCE: present invention relates to new antibodies able to bind to antigen CD123 (α-receptor of interleukin 3 or IL-3Rα), and can be used in medicine. Invention also enables to obtain immunostimulating conjugates based on antibodies to CD123 and various anticancer agents. In addition, the invention can be used for diagnosing and treating those types of cancer, cells of which there is increased expression of CD123 antigen, e.g. acute myeloid leukemia, lymphoblastic or lymphocytic leukemia or other malignant B-cell tumors.
EFFECT: disclosed are anti-CD123 antibodies and conjugates and derivatives thereof.
59 cl, 30 ex, 11 tbl, 33 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| SEPARATION OF ANTIBODIES WITH THREE LIGHT CHAINS USING CATION EXCHANGE CHROMATOGRAPHY | 2018 |
|
RU2795432C2 |
| METHODS OF TREATING USING ANTI-CD123 IMMUNOCONJUGATES | 2019 |
|
RU2816847C2 |
| POLYPEPTIDES RECRUITING T-CELLS, CAPABLE OF BINDING CD123 AND ALPHA/BETA TCR | 2017 |
|
RU2775063C2 |
| ANTIBODIES AND ANTIBODY-DRUG CONJUGATES SPECIFIC TO CD123 AND THEIR USE | 2018 |
|
RU2789150C2 |
| VARIANT CD3 BINDING DOMAINS AND THEIR USE IN COMBINATION THERAPY FOR TREATMENT OF DISEASES | 2019 |
|
RU2810222C2 |
| CD123-SPECIFIC CHIMERIC ANTIGENIC RECEPTORS FOR CANCER IMMUNOTHERAPY | 2015 |
|
RU2727290C2 |
| CONJUGATES OF BINDER AND ACTIVE SUBSTANCE (ADC) HAVING ENZYMATICALLY CLEAVABLE GROUPS | 2017 |
|
RU2761390C2 |
| CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
| IMMUNE CELLS EXPRESSING INVERSE UNIVERSAL CHIMERIC ANTIGEN RECEPTOR, FOR TARGETING VARIOUS MULTIPLE ANTIGENS AND METHOD FOR PRODUCTION AND USE THEREOF FOR TREATING CANCER, INFECTIONS AND AUTOIMMUNE DISEASES | 2019 |
|
RU2824391C2 |
